Search the Newsreel

Resultados por encima de lo esperado: Incyte Corporation acaba de superar las previsiones de los analistas, y estos han ido actualizando sus modelos

Incyte (INCY) Wins European Approval For Opzelura In Adult Atopic Dermatitis

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. European Commission approves Opzelura (ruxolitinib) cream as the first steroid free topical JAK inhibitor for adults with moderate atopic dermatitis in the EU. …

No-Moat Incyte Faces Jakafi Patent Cliff as Focus Remains on Opzelura and Expanding Portfolio

Incyte is confronting the patent expiration of its key hematology drug, Jakafi, in 2028. The company is shifting its focus to Opzelura, a dermatology drug based on the same active ingredient, and developing a broader oncology and dermatology portfolio to drive future growth. While …

Incyte Earnings: Opzelura Settlement and Latarcibart Improve Outlook Ahead of Jakafi Patent Loss

Incyte Number of Employees 2026 | Employee Count & Headcount Data

Incyte Corp. (INCY) reported approximately 2,931 employees worldwide as of March 2026, marking a 19.4% growth since 2023. The company is actively hiring, with 199 job postings in 2026, though new postings per month have decreased. The workforce is primarily concentrated in the United …

Incyte Shares Retreat After Best Day In A Year Despite Opzelura EU Nod

Incyte's shares fell by about 2% after a significant gain driven by strong Q2 results and raised full-year 2026 net sales guidance. The retreat occurred despite the European Commission approving its Opzelura cream for moderate eczema. Analysts remain positive about Incyte's commercial strength and …

INCY Maintained by RBC Capital -- Price Target Raised to $109

RBC Capital has maintained its 'Sector Perform' rating for Incyte (INCY) while increasing its price target from $99 to $109. Despite this, GuruFocus indicates that INCY is currently 27.1% overvalued with a GF Value of $100.46 compared to its price of $127.67, and insider …

INCY Maintained by Guggenheim -- Price Target Raised to $150

Guggenheim has maintained a 'Buy' rating for Incyte (INCY) and raised its price target from $136.00 to $150.00. Despite this positive analyst outlook, Incyte is considered 27.3% overvalued according to GuruFocus's GF Value™ and has seen net insider selling of $5.4 million over the …

Incyte Analysts Raise Their Forecasts After Upbeat Q2 Results

Incyte (NASDAQ: INCY) reported stronger-than-expected second-quarter results and upwardly revised its full-year sales guidance, leading several analysts to raise their price targets. The biopharmaceutical company exceeded earnings and revenue estimates, driven by broad-based sales growth and pipeline progress. Despite the improved outlook, Incyte's updated …

TD Cowen Adjusts Incyte Price Target to $138 From $124, Maintains Buy Rating

TD Cowen has raised its price target for Incyte Corporation (INCY) shares to $138 from $124, while reiterating a Buy rating on the stock. This adjustment reflects a positive outlook from the analyst firm on the biopharmaceutical company, which specializes in therapies for cancer …

Guggenheim raises Incyte stock price target to $150 on strong results

Guggenheim has increased its price target for Incyte Corp. shares to $150 following the company's strong second-quarter financial results, which exceeded analyst expectations for revenue and net product sales. Incyte's stock surged by 12% and the company raised its 2026 guidance, citing robust commercial …

Top 3 Health Care Stocks That May Implode This Month

This article identifies three healthcare stocks—Incyte Corp (INCY), Tenet Healthcare Corp (THC), and AtriCure Inc (ATRC)—that are considered overbought based on their Relative Strength Index (RSI) values exceeding 70. All three companies recently reported better-than-expected earnings and have seen significant stock price gains, suggesting …

Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis

The European Commission approval is based on Phase 3b TRuE‑AD4 data which demonstrated that Opzelura® (ruxolitinib) cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24, and was well tolerated 1,2,3 WILMINGTON, Del., July 29, 2026--(BUSINESS WIRE)--Incyte …

Incyte (INCY) Stock Rallies As Profit Strength Fuels Diversification Debate

Incyte Corporation (INCY) enters July 28 report with weekly uptrend intact

The setup matters because recent biotechnology strength is being weighed against lighter weekly trading activity.

Incyte Corporation Stock 12‑Month Price Target Raised to $119.67, Implies 1% Upside

Incyte Corporation's average 12-month price target has increased from $116.62 to $119.67, based on estimates from 21 analysts, suggesting a 1% upside from its July 27 closing price. The consensus rating for the stock remains "Buy" among 29 analysts, with a breakdown of 12 …

INCYTE CORP 2Q 2026: Revenue $1.67B, EPS $2.81— 10-Q Summary

INCYTE CORP reported its second-quarter 2026 results, showing revenue of $1.67 billion and diluted EPS of $2.81, both increasing significantly from the prior year. This growth was driven by strong product sales, higher royalties, and brand momentum across several key products. The company also …

Oppenheimer raises Incyte stock price target to $120 on revenue beat

Oppenheimer has increased its price target for Incyte Corp. (NASDAQ:INCY) to $120 from $107, maintaining a Perform rating, following the company's strong second-quarter 2026 results. Incyte reported total revenue of $1.67 billion, surpassing both Oppenheimer's and consensus estimates, driven by robust sales of Jakafi …

Incyte Stock Hits 52-Week High - Here's Why - Incyte (NASDAQ:INCY)

Incyte (NASDAQ: INCY) recently reported better-than-expected second-quarter results, beating analyst estimates for both earnings and revenue. The biopharmaceutical company raised its full-year sales guidance, driven by strong growth in products like Opzelura and its hematology and oncology portfolio. CEO Bill Meury emphasized that Incyte …

Incyte forecasts $5.130B-$5.260B 2026 net sales as Opzelura guidance rises to $1.050B-$1.1B after CMS settlement

Earnings Call Insights: Incyte Corporation (INCY) Q2 2026 MANAGEMENT VIEW * "At the start of the year, we laid out a plan to move Incyte from reliance on a cornerstone product to a company with multiple growth drivers," William Meury (CEO & Director) said, …

Incyte Q2 Revenue Jumps 38%, Raises FY26 Sales Guidance

(RTTNews) - Incyte Corp. (INCY) on Tuesday reported an increase in second-quarter earnings and revenue, driven by strong growth across its commercial portfolio. The company also raised its full-year 2026 sales guidance. Second-quarter net income increased to $585.6 million or $2.81 per share, from …

A Noteworthy Decision By Lee Heeson As Acquires $130K In Incyte Stock Options

Lee Heeson, EVP at Incyte (NASDAQ: INCY), recently acquired stock options for 15,423 shares, valued at approximately $130,864. This action is viewed as a positive indicator by insiders for the company's future stock performance. Incyte has demonstrated strong revenue growth and gross margins, though …

Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates

Incyte announced strong second-quarter 2026 financial results, with total revenue of $1.67 billion and net sales of $1.49 billion, representing increases of 38% and 40% respectively, driven by robust performance across its commercial portfolio, particularly Opzelura and Jakafi. The company also raised its full-year …

Compared to Estimates, Incyte (INCY) Q2 Earnings: A Look at Key Metrics

For the quarter ended June 2026, Incyte (INCY) reported revenue of $1.67 billion, up 37.7% over the same period last year. EPS came in at $3.09, compared to $1.57 in the year-ago quarter. The reported revenue represents a surprise of +14.71% over the Zacks …

Incyte lifts annual revenue forecast after settlement with CMS

Incyte Corp. raised its annual revenue forecast after settling a lawsuit with the U.S. government regarding Medicaid rebates for its eczema cream, Opzelura. The settlement is expected to add $300 million to $310 million to Opzelura's net sales for 2026 and contributed significantly to …

Incyte (INCY) Q2 Earnings and Revenues Top Estimates

Incyte (INCY) came out with quarterly earnings of $3.09 per share, beating the Zacks Consensus Estimate of $2 per share. This compares to earnings of $1.57 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings …

Incyte (NASDAQ:INCY) Posts Better-Than-Expected Sales In Q2 CY2026 But Full-Year Sales Guidance Misses Expectations Significantly

Incyte (NASDAQ:INCY) reported stronger-than-expected Q2 CY2026 results, with revenue reaching $1.67 billion and adjusted EPS of $3.09, both exceeding analyst estimates. However, the company's full-year revenue guidance of $5.20 billion, while increased, still fell 9.2% below analysts' expectations. The biopharmaceutical company demonstrated strong revenue …

Earnings Flash (INCY) Incyte Corporation Reports Q2 Revenue $1.67B, vs. FactSet Est of $1.50B

Incyte Corporation (INCY) reported its Q2 revenue at $1.67 billion, surpassing the FactSet estimate of $1.50 billion. This financial update indicates stronger-than-expected performance for the biotechnology company during the second quarter. The report also highlights other recent analyst adjustments and drug development news for …

What to Expect From Incyte's Q2 2026 Earnings Report

What To Expect From Incyte's (INCY) Q2 Earnings Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting results this Tuesday before the bell. Here's what to look for. Incyte beat analysts' revenue expectations last quarter, reporting revenues of $1.27 billion, up 20.9% year on year. …

Incyte posts Q2 2026 revenue $1.67B, net income $586M; raises 2026 net sales outlook

Incyte reported strong second-quarter 2026 financial results, with GAAP total revenue reaching $1.67 billion and GAAP net income at $585.6 million, largely due to increased product sales and a one-time accounting benefit from Opzelura. The company saw a 40% year-over-year increase in total net …

Incyte Revenue Rises 38 Percent to $1.67 Billion in Q2

Incyte (INCY) reported a significant increase in its second-quarter 2026 revenue, with total revenue rising 38% to $1.67 billion and net sales up 40% to $1.49 billion. The company attributed this growth to strong performance in its Hematology and Oncology products and a CMS …

Incyte Non-GAAP EPS of $3.09 beats by $0.94, revenue of $1.67B beats by $180M

* Incyte press release [https://seekingalpha.com/pr/20596936-incyte-reports-second-quarter-2026-financial-results-and-provides-business-updates] (INCY [https://seekingalpha.com/symbol/INCY]): Q2 Non-GAAP EPS of $3.09 beats by $0.94. * Revenue of $1.67B (+36.9% Y/Y) beats by $180M. * Total revenue of $1.67 billion and total net sales of $1.49 billion in the second quarter of 2026, an …

Incyte (INCY) Earnings Date and Reports 2026 $INCY

Incyte Corporation (NASDAQ: INCY) lifts H1 2026 profit on drug sales and Vega deal

Incyte Corporation 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:INCY) 2026-07-28

Incyte Corporation reported strong Q2 2026 earnings, with total revenue up 38% year-over-year to $1.67 billion and net sales up 40% to $1.49 billion, driven by demand across its product portfolio and a one-time CMS settlement benefit. The company is transitioning from reliance on …

Incyte raises sales outlook as Opzelura, cancer portfolio fuel strong quarter (INCY:NASDAQ)